167 Views
C3. Skin and soft tissue
Poster Session: Skin and Soft Tissue
Pts who received ≥1 OMC outpatient Rx from a large US claims database (10/2018-9/2020) were identified. Pts were classified as ABSSSI or CABP cohort based on presence of ICD-10 code near (-90 d to +30 d) OMC Rx. Within each diagnosis, pts were classified as complicated if any of the following infections were identified in the pre-period (-90 d to + 5 d) (ABSSSI: osteomyelitis (OST), sepsis/bacteremia (S/B), endocarditis, implant, necrotizing fasciitis, meningitis; CABP: severe pneumonia, lung abscess, S/B, endocarditis, meningitis). Risk of inpatient admissions (IP), ED visits, outpatient visits (OP) were compared between the following 2 periods: 30 days pre- and 30-days post-OMC Rx.
Results: During study period, 258 OMC outpatient Rx met inclusion criteria: 189 were ABSSSI and 69 were CABP. Among the 189 ABSSSI pts, 83 were complicated. Most common ABSSSI complicated were OST (53%), S/B (33%), and implant infection (21%). Among the 69 CABP pts, 20 were COM. Most common CABP complicated were S/B (80%) and severe pneumonia (25%). Comparison of HRU in the 30 days pre- to the 30-day post-OMC Rx period are shown in Tables 1 and 2. Among complicated ABSSSI pts, IP decreased by 38% (41% vs 25%; p< 0.05) while ED visits and OP were similar. Among non- complicated ABSSSI pts, IP decreased by 61% (17% vs 7%; p< 0.05), ED visits decreased by 88% (16% vs 2%; p< 0.01) while OP were similar. Among complicated CABP pts, IP decreased by 75% (80% vs 20%; p< 0.01), ED decreased by 100% (40% vs 0%; p< 0.001) while OP were similar. Among non- complicated CABP pts, IP decreased by 75% (33% vs 8%; p< 0.01), while ED visits and OP were similar. Table 1. Comparison of HRU in the 30-day pre-OMC Rx vs 30-day post-OMC Rx period among ABSSSI ptsTable 2. Comparison of HRU in the 30-day pre-OMC Rx vs 30-day post-OMC Rx period among CABP pts
Conclusion:
This study provided the first real world characterization of pts treated with OMC for ABSSSI or CABP. Patients who received OMC had lower HRU in the 30-days post- OMC Rx period relative to the 30-day pre-OMC Rx period.
Thomas Lodise, Jr., PharmD, PhD
Professor, Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Albany, New York, United States
Disclosure: Astra-Zeneca (Consultant)Bayer (Consultant)DoseMe (Consultant, Advisor or Review Panel member)ferring (Consultant)genentech (Consultant)GSK (Consultant)Melinta (Consultant)merck (Consultant, Independent Contractor)nabriva (Consultant)paratek (Consultant, Advisor or Review Panel member, Speaker's Bureau)shionogi (Consultant, Advisor or Review Panel member, Speaker's Bureau)Spero (Consultant)tetraphase (Consultant)Venatrox (Consultant)
Kyle Gunter, PharmD, MBA
Paratek Pharmaceuticals, Inc.
King of Prussia, Pennsylvania, United States
Disclosure: Paratek Pharmaceuticals, Inc. (Employee, Shareholder)
Mauricio Rodriguez, Jr., PharmD, BCPS, BCCCP, BCIDP
Senior Director, Medical Science
Paratek Pharmaceuticals, Inc.
King of Prussia, Pennsylvania, United States
Disclosure: Paratek Pharmaceuticals, Inc. (Employee, Shareholder)
Fan Miu, PhD
Analysis Group
Boston, Massachusetts, United States
Disclosure: Analysis Group (Employee, Other Financial or Material Support, Analysis Group received consulting fees from Paratek Pharmaceuticals, Inc.)
Emily Gao, MS, MPH
Analysis Group, Inc.
Boston, Massachusetts, United States
Disclosure: Merck & Co., Inc. (Consultant)
Danni Yang, BA
Analysis Group
Boston, Massachusetts, United States
Disclosure: Analysis Group (Employee, Other Financial or Material Support, Analysis Group received consulting fees from Paratek Pharmaceuticals, Inc.)
Steve Sandor, JD, MBA
Paratek Pharmaceuticals, Inc.
King of Prussia, Pennsylvania, United States
Disclosure: Paratek Pharmaceuticals, Inc. (Employee, Shareholder)
Gail Berman, MD
Paratek Pharmaceuticals, Inc.
King of Prussia, Pennsylvania, United States
Disclosure: Paratek Pharmaceuticals, Inc. (Employee, Shareholder)